1. High Performance IOL Power Calculation….
at the push of a button
OIS, San Diego
16th April 2015
Michael Mrochen, CTO and Co Founder
2. IOL Power Calculation
It takes years of learning and experience!
Google search result on “IOL Power Calculation”
3. How to match the best outcomes?
NHS Standard
85% within +/- 1D
55% within +/- 0.5D
Royal College of Ophthalmic Cataract Surgeons Guidelines, Gale et al, 2006
More recently
“With modern optical biometry for the majority of
patients, informed formula choice and IOL
constant optimisation outcomes of more than 90%
within ±1 D and more than 60% within ±0.5 D of
target are achievable”.
R.Sheard, Optimising Biometry for best outcomes in cataract surgery, Eye, 2014
To achieve these results takes time for every
patient and considerable expertise
4. The Problem
• Historical IOL power formulae are:
– Good for the “average” refractive outcome (SEQ)
– Poor for predicting the individual refractive outcome
• High complexity driven by variety of formulae available for
– Short or long eyes
– Astigmatic eyes
– Post-refractive surgery eyes
• Improving refractive outcomes based on formulae requires:
– Experience
– Time to optimize and implement for the individual patient
– Reliable historical clinical data for A-constant optimization
5. Mirricon –A new Ocular Biometer for
High Performance IOL Power Calculation
•Results at the push of a button assuring:
• Convenience – minimal training time and
improved clinic throughput
•Easy decisions without great expertise and
experience delivering:
• Predictable outcomes - Excellent and
consistent results every time
• Safety – Reducing the possibility of
human error in IOL Power calculation
•One preoperative solution
for all types of eyes
7. Physical Optical Testing
with Model Eyes
First in human use
January 2014
May 2014
May 2015
POC – study in
100 cataract eyes
Status of DevelopmentApril 2014
Device
development
Multi Million Investment
4 patents filed (1 approved)
R&D Project
2010
What are we looking for?
Partnership opportunities
with IOL and Device
companies
Investment partners to
execute our roadmap for
commercialization